Experienced in Focal Segmental Glomerulosclerosis

Yung-ming E. Chen

National Taiwan University Hospital Bei Hu Branch
TPQ, TW 
Experienced in Focal Segmental Glomerulosclerosis
National Taiwan University Hospital Bei Hu Branch
TPQ, TW 
OverviewLocationsClinical Research

Overview

Yung-ming Chen practices in Taiwan. Chen is rated as an Experienced expert by MediFind in the treatment of Focal Segmental Glomerulosclerosis. Their top areas of expertise are Chronic Kidney Disease, Hyperaldosteronism, Adrenal Gland Adenoma, End-Stage Renal Disease (ESRD), and Coronary Artery Bypass Graft (CABG).

Their clinical research consists of co-authoring 115 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles and participated in 1 clinical trial in the study of Focal Segmental Glomerulosclerosis.

Locations

National Taiwan University Hospital Bei Hu Branch
TPQ, Taiwan
Other Locations
Bei Hu Branch, TPQ, Taiwan
Yunlin Branch, Dawan, TNQ, Taiwan
No.7, Chung Shan South Road, 100, TPQ, Taiwan
No. 7, Chung Shan South Road, 100, TPQ, Taiwan
No. 7, Chung Shan S. Rd, Zhongzheng Dist, TPQ 10002, Taiwan
No. 7, Chung Shan South Road, TPQ, Taiwan
Yun Lin Branch, Yun Lin, TPQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2025
Intervention Type: Drug
Study Drugs: Sparsentan, Irbesartan
Study Phase: Phase 3
A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy
A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drug: Mezagitamab
Study Phase: Phase 1
View 1 Less Clinical Trial

115 Total Publications

Predictive factors and survival associated with varying degrees of cytopenia in patients undergoing chronic Hemodialysis: A cohort study.
Predictive factors and survival associated with varying degrees of cytopenia in patients undergoing chronic Hemodialysis: A cohort study.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: August 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chen's expertise for a condition
ConditionClose
      View All 16 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile